Published in Dig Dis Sci on June 01, 2008
Primary sclerosing cholangitis. Can J Gastroenterol (2008) 1.17
The therapeutic potential of milk thistle in diabetes. Rev Diabet Stud (2014) 0.77
Silymarin for the treatment of chronic liver disease. Gastroenterol Hepatol (N Y) (2007) 0.77
Management of primary sclerosing cholangitis. World J Hepatol (2011) 0.76
A model to predict survival in patients with end-stage liver disease. Hepatology (2001) 18.06
High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol (2001) 2.61
Primary sclerosing cholangitis. N Engl J Med (1995) 1.94
Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol (1998) 1.76
Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology (1997) 1.64
Primary sclerosing cholangitis. Hepatology (1999) 1.52
Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology (1983) 1.49
A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology (2001) 1.31
Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol (1989) 1.30
Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol (1982) 1.30
Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J Appl Toxicol (1992) 1.30
Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology (1999) 1.26
Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology (1996) 1.13
A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol (1993) 1.10
The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology (1999) 1.05
Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology (2000) 1.03
Clinical studies with silymarin: fibrosis progression is the end point. Hepatology (2001) 0.82
Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers. Ital J Gastroenterol (1990) 0.79
Silybin inhibition of human T-lymphocyte activation. Int J Tissue React (1988) 0.79
Effects of silibinin and antioxidants on high glucose-induced alterations of fibronectin turnover in human mesangial cell cultures. J Pharmacol Exp Ther (1996) 0.77
Stabilization of isolated rat liver plasma membranes by treatment in vitro with silymarin. Arzneimittelforschung (1974) 0.75
Primary sclerosing cholangitis: emerging new promising therapies. J Clin Gastroenterol (2000) 0.75
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 5.29
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology (2003) 4.84
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol (2005) 4.65
Global epidemiology of hepatitis B virus. J Clin Gastroenterol (2004) 4.48
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (2015) 3.96
Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med (2013) 3.52
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology (2004) 2.98
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology (2009) 2.75
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology (2010) 2.55
Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol (2006) 2.48
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol (2011) 2.38
Non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2002) 2.32
Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 2.28
Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl (2002) 2.25
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology (2005) 2.15
Incidence of minor complications and time lost from normal activities after screening or surveillance colonoscopy. Gastrointest Endosc (2006) 2.14
Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol (2004) 2.11
Nonalcoholic fatty liver disease. Ann Epidemiol (2007) 2.09
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology (2004) 2.09
Gender differences in academic productivity and leadership appointments of physicians throughout academic careers. Acad Med (2011) 2.03
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology (2010) 1.98
The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol (2004) 1.92
Primary biliary cirrhosis. Lancet (2003) 1.90
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology (2009) 1.90
The North American Study for the Treatment of Refractory Ascites. Gastroenterology (2003) 1.87
Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology (2002) 1.69
Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl (2007) 1.69
Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol (2003) 1.68
Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver Int (2009) 1.68
Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis (2011) 1.68
Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? J Hepatol (2004) 1.65
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci (2005) 1.63
Identification of differentially expressed genes in response to dietary iron deprivation in rat duodenum. Am J Physiol Gastrointest Liver Physiol (2005) 1.63
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
Hereditary hemochromatosis: time for targeted screening. Ann Intern Med (2008) 1.60
Association of hepatic iron overload with invasive fungal infection in liver transplant recipients. Liver Transpl (2006) 1.59
Primary sclerosing cholangitis. Lancet (2013) 1.59
Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol (2002) 1.58
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.56
Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J Lipid Res (2011) 1.54
Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs (2013) 1.50
Complications after ERCP in patients with primary sclerosing cholangitis. Gastrointest Endosc (2007) 1.49
Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol (2005) 1.48
Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology (2003) 1.48
Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol (2003) 1.47
Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis (2007) 1.46
Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology (2008) 1.45
Research productivity of graduates from 3 physician-scientist training programs. Am J Med (2008) 1.44
The value of observational research in liver diseases. Hepatology (2011) 1.43
The management of chronic hepatitis B in Asian Americans. Dig Dis Sci (2011) 1.42
Effect of iron depletion on serum markers of fibrogenesis, oxidative stress and serum liver enzymes in chronic hepatitis C: results of a pilot study. Liver Int (2007) 1.42
Iron overload related to excessive vitamin C intake. Ann Intern Med (2003) 1.41
Utility of liver biopsy in bone marrow transplant patients. J Gastroenterol Hepatol (2008) 1.41
Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology (2007) 1.39
Abnormal liver test results on routine screening. How to evaluate, when to refer for a biopsy. Postgrad Med (2004) 1.39
Use of ursodeoxycholic acid in patients with liver disease. Curr Gastroenterol Rep (2002) 1.39
The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health (2007) 1.35
Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med (2003) 1.33
Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology (2004) 1.33
Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Liver Int (2007) 1.30
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol (2012) 1.28
Correlation of proton transverse relaxation rates (R2) with iron concentrations in postmortem brain tissue from alzheimer's disease patients. Magn Reson Med (2007) 1.27
Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology (2003) 1.26
The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia. Gastroenterology (2004) 1.26
Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. Hepatology (2012) 1.26
Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology (2009) 1.26
Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol (2006) 1.25
MicroRNAs in common human diseases. Genomics Proteomics Bioinformatics (2012) 1.25
Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol (2004) 1.24
Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg (2003) 1.24
Method for microRNA isolation from clinical serum samples. Anal Biochem (2012) 1.23
Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res (2011) 1.23
Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol (2002) 1.21
Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology (2002) 1.20
Primary sclerosing cholangitis. Can J Gastroenterol (2008) 1.17
Bone disease in patients with primary sclerosing cholangitis. Gastroenterology (2010) 1.15
The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int (2012) 1.15
The effect of periodic monitoring and feedback on screening colonoscopy withdrawal times, polyp detection rates, and patient satisfaction scores. Gastrointest Endosc (2010) 1.15
Human leukocyte antigen Class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. J Hepatol (2002) 1.14
Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol (2006) 1.13